Overview

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

Status:
RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
Phase:
PHASE2
Details
Lead Sponsor:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.